Sciwind is a science-driven, international biotech, focusing on metabolic diseases, especially fibrotic diseases. Sciwind is committed to developing first-in-class or best-in-class biotechnology-derived therapeutic products with independent intellectual property rights. The primary focus for Sciwind is NASH, particularly steatohepatitis, liver inflammation and liver fibrosis.
The R&D team consisting of experts from the Recruitment Program of Global Experts, oversea returnees and local experts specialized in the research and development of innovative drugs, including drug design, process development, pharmacology and toxicology. The R&D team of Sciwind has strong independent research and development capabilities. In recent years, team members have completed three NDAs, one of which has received a new drug certificate, as well as three INDs , and conducted more than seven Phase II / III clinical trials.
Sciwind has its core technology platforms, consisting of oral peptide formulation, liver targeting drug delivery technology and animal models of fibrotic diseases, etc. Based on these technologies, Sciwind has established its pipeline with five candidate drugs, all of which are innovative new drugs.
Sciwnd's management team, pipeline, and R&D capabilities have been recognized by many investment institutions. Sciwnd has raised 230 million RMB in its Series A financing, leading by Legend Capital, followed by Shiyu Capital, and Hangzhou Haibang Venture Management, providing strong financial support for its long-term development.
Sciwnd is an open-minded company, while vigorously promoting independent research and development, Sciwind is also actively pursuing strategic cooperation, seeking cooperation opportunities worldwide, planning to license in high-quality products and technologies that fulfil the unmet medical needs. This strategy also maximizes our R&D capabilities and resources for clinical development, and enable Sciwind to deliver leading innovative drugs to patients with reasonable cost.